Heterocyclic compound

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10696651
APP PUB NO 20190169166A1
SERIAL NO

16323863

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I):

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
TAKEDA PHARMACEUTICAL COMPANY LIMITEDOSAKA-SHI OSAKA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Asano, Yasutomi Kanagawa, JP 28 151
Banno, Hiroshi Kanagawa, JP 37 313
Cary, Douglas Robert Tokyo, JP 10 79
Fujimoto, Jun Kanagawa, JP 164 3308
Kojima, Takuto Kanagawa, JP 34 166
Kurasawa, Osamu Kanagawa, JP 15 47
Liu, Xin Shanghai, CN 657 8645
Takagi, Terufumi Kanagawa, JP 15 156

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 30, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 30, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00